RM Sobecks, L Rybicki, M Yurch… - Bone Marrow …, 2011 - nature.com BU and CY is a common conditioning regimen for allogeneic hematopoietic progenitor cell transplantation (HPCT). Iv BU is increasingly used in place of the oral formulation for conditioning. We compared the outcomes of 135 consecutively treated AML and myelodysplastic syndrome patients ...
M Andion, B Molina, M Gonzalez-Vicent… - Journal of Pediatric …, 2011 - journals.lww.com We analyzed the outcome in 22 children with refractory or relapsed non-Hodgkin lymphoma who underwent autologous peripheral blood progenitor cell transplantation between 1994 and 2009. The conditioning regimen used in all patients consisted of busulfan and ... Related articles - All 4 versions
FR Kerbauy, M Rodrigues, SFP de Souza… - Leukemia & …, 2011 - ncbi.nlm.nih.gov 1. Leuk Lymphoma. 2011 Feb;52(2):321-4. Allogeneic hematopoietic stem cell transplant after intravenous busulfan and fludarabine conditioning. Kerbauy FR, Rodrigues M, de Souza Santos FP, Sobrinho JN, Kutner JM, Torres MA, Ribeiro AA, de Lima M, Hamerschlak N. ... Related articles - All 2 versions
[HTML] from hematologylibrary.orgNS Majhail, R Brazauskas, JD Rizzo… - …, 2011 - bloodjournal.hematologylibrary.org Risks of secondary solid cancers among allogeneic hematopoietic cell transplant (HCT) recipients who receive conditioning without total body irradiation are not well known. We evaluated the incidence and risk factors for solid cancers after HCT using high-dose busulfan- ... Cited by 3 - Related articles - All 3 versions
X Tang, M de Lima, W Wei, A Chiattone… - Biology of Blood and …, 2011 - bbmt.org ... Early Mixed Chimerism Does Not Alter Long-Term Prognosis for Patients Receiving IV Busulfan-Fludarabine (Iv Bu-Flu) With Allogeneic Stem Cell Transplantation for AML/MDS. X. Tang: Affiliations. Jiangsu Institute of Hematology, Soochow, China. ,; M. de Lima: Affiliations. ... Cached - All 2 versions
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
安全保密
